Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Gal Rubinstein und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Photopheresis, Graft Rejection, Heart Transplantation, Postoperative Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Extracorporeal photopheresis (ECP) has gained recognition as a valuable adjunctive antirejection therapy, particularly in heart‐transplantation (HT) patients at elevated risk for rejection or those experiencing recurrent antibody‐mediated rejection (AMR) despite appropriate treatment. We evaluated the safety and clinical effects of ECP in HT recipients with high immunologic risk.
Methods
All HT recipients who underwent ECP between February 2020 and January 2024 were included in this retrospective, single‐center study.
Results
Fifteen patients who underwent ECP were identified. Twelve patients completed ECP and were followed for a median of 11.2 months (3.9–19.9). The time from transplant to ECP initiation was 5.3 years (1.3–13). The most common indication for ECP was AMR (60%). During ECP, immunosuppression regimens were maintained or de‐escalated in 93% of the patients. Reduction in donor specific antibodies (DSA), peripheral gene expression profiling (GEP), and donor‐derived cell‐free DNA (dd‐cfDNA) levels were observed in 64%, 57%, and 67% of the patients, respectively. Eighty‐three percent of the patients were free from rejection during the follow‐up period. Overall survival was 87%, and no deaths were related to ECP.
Conclusion
In our single‐center experience, ECP resulted in a decrease in immunosuppression use, and a reduction in DSA, GEP, and dd‐cfDNA levels with a high freedom‐from‐rejection rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiology, New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
- University of Barcelona (UB), Barcelona, Spain.
ORCID-Profile: Gal Rubinstein, Cathrine M Moeller, Daniel Oren, Dor Lotan, Afsana Rahman, Jayant K Raikhelkar, Ersilia M DeFilippis, Kevin J Clerkin
Förderung
- NIGMS NIH HHS
Zitieren
APA
Rubinstein, G., Valledor, A. F., Moeller, C. M., Baranowska, J., Oren, D., Oh, D. K. T., Bae, D., Yunis, A., Lotan, D., Rahman, A., Raikhelkar, J. K., Fried, J. A., DeFilippis, E. M., Clerkin, K. J., Latif, F., Sayer, G. T., & Uriel, N. (2025). Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.70247
Vancouver
Rubinstein G, Valledor AF, Moeller CM, Baranowska J, Oren D, Oh DKT, et al. Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience. Clinical Transplantation. 2025. doi:10.1111/ctr.70247
BibTeX
@article{Rubinstein2025,
author = {Rubinstein, Gal and Valledor, Andrea Fernandez and Moeller, Cathrine M and Baranowska, Julia and Oren, Daniel and Oh, David Kyung Taek and Bae, David and Yunis, Adil and Lotan, Dor and Rahman, Afsana and Raikhelkar, Jayant K and Fried, Justin A and DeFilippis, Ersilia M and Clerkin, Kevin J and Latif, Farhana and Sayer, Gabriel T and Uriel, Nir},
title = {Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single‐Center Experience},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70247}
}
EUVIMED